Cancers of the central nervous system are the most common solid tumors in childhood. As with adults, Glioblastoma (GBM) remains an equally devastating disease in children, with substantial morbidity and mortality. The reported median survival in pediatric GBM ranges from 13 to 73 months with a 5-year survival of less than 20%. Tumor treating fields (TTFields) are a loco-regional, intermediate frequency (200 kHz), low intensity (1-4 V/cm), non-invasive antimitotic therapy delivered via transducer arrays placed on the patient's skin and connected to the portable device. TTFields demonstrated safety and efficacy in Phase 3 studies of adult patients with GBM, which led to FDA approval for recurrent use as monotherapy and in newly diagnosed GBM with adjuvant temozolomide. NCCN Guidelines also support the use of TTFields with Category 1 recommendations for newly diagnosed GBM and category 2b for recurrent GBM. A post-market analysis examined the safety data in pediatric patients treated off-label with TTFields (Optune®, Novocure) from January 2015 - August 2021. 81 pediatric (<18 years) patients received TTFields therapy during this period. Of those, 54 were male and 27 female, median age of 13 years (range 3-17 years). The most common diagnosis was newly diagnosed GBM (49%) followed by recurrent GBM (33%). 63% of patients reported at least one adverse event (AE), 170 AEs in total, during the observation period. There were 28 serious AEs reported by 14% of patients, the most common being seizures (5%). No serious AEs were considered related to device use. Of the 170 AEs, 99 were considered potentially related to TTFields including heat sensation (12%), electric sensation (10%), and headache (12%). As has been observed in the adult population, the most common AE related to TTFields use reported in pediatric patients was medical device site reactions of the skin reported by 36% of patients. Oncology nurses play an important role in the early detection, prevention, and effective management of AEs, which are critical to optimizing patient adherence to therapy. The post marketing surveilance data shown here support the safety and tolerability of TTFields in pediatric patients, while published recommendations for the care of TTFields dermatologic AEs may assist nurses in minimizing AEs in these patients receiving TTFields.